Cell Therapy for Patients with Ischemic Heart Failure

Results are promising but still preliminary.

Cell therapy to regenerate cardiac function has stimulated substantial interest that so far outpaces any evidence of benefits. Studying the therapy is complex because of its numerous approaches. In a manufacturer-sponsored, phase IIb, investigational trial, researchers assessed an augmented, autologous marrow preparation in 126 patients with ischemic cardiomyopathy (mean age, 65; 92% men).

Participants had left ventricular ejection fraction of ≤35%, severe symptoms (New York Heart Association [NYHA] class III or IV), an implantable defibrillator, and lack of eligibility for mechanical revascularization. Almost all were treated with antiplatelet therapy, beta blockers, and statins; most also received ACE inhibitors. Patients were randomized t…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)